Effect low dose ketamine in late brain injury from ruptured intracranial aneurysm

Effect of low dose intravenous Ketamine on Delayed Cerebral Ischemia and long-term outcome in aneurysmal Subarachnoid Haemorrhage patients – A Randomised Controlled Trial

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/051589

Enrollment

104

Registered

2023-04-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I609- Nontraumatic subarachnoid hemorrhage, unspecified

Interventions

Intervention1: Ketamine: Patients in experimental group will receive intravenous ketamine initiated following diagnosis at 0.25mg/kg/h24 over 4 hours, everyday, for a period of 5 days. Control Interve

Eligibility

Inclusion criteria

Inclusion criteria: 1.All aSAH patients 18-70 years of age 2.Admitted to the hospital within 72 hours of ictus 3.Ruptured anterior cerebral circulation aneurysm with subarachnoid hemorrhage on admission cranial computed tomography (CT) scan with modified Fisher grade of 3-4 4.World Federation of Neurological Surgeons (WFNS) grade 1 to 3 5.Informed Consent for participation in the study

Exclusion criteria

Exclusion criteria: 1.Refusal of consent 2.Patients with multiple aneurysms 3.Baseline Systolic Blood Pressure (SBP) >200 mm Hg 4.Patients with intraoperative iatrogenic injury or inadvertent clipping of intracranial arteries 5.Any contraindication for the use of ketamine like acute psychosis, previous known ischemic heart diseases. 6.Mean arterial pressure (MAP) increases by more than 20% from baseline (on that day) following infusion

Design outcomes

Primary

Measure	Time frame
1.To study the effect of low dose intravenous ketamine on the incidence of DCI and severity of cerebral infarction associated with DCI on brain imaging. 2.To study the functional outcome at 3 months post-aSAH ictus in both groupsTimepoint: 1. 10days or till discharge whichever earlier 2. 3 months	—

Secondary

Measure	Time frame
1.To study the severity of vasospasm in aSAH patients receiving low dose intravenous ketamine infusion as compared to normal saline group 2.To study the impact of low dose intravenous ketamine on the duration of hospital stay (including ICU stay) as compared to normal saline 3.To study the adverse effects of low dose intravenous ketamine as compared to normal saline on aSAH patientsTimepoint: 10days or till discharge whichever earlier	—

Measure

Time frame

1.To study the severity of vasospasm in aSAH patients receiving low dose intravenous ketamine infusion as compared to normal saline group 2.To study the impact of low dose intravenous ketamine on the duration of hospital stay (including ICU stay) as compared to normal saline 3.To study the adverse effects of low dose intravenous ketamine as compared to normal saline on aSAH patientsTimepoint: 10days or till discharge whichever earlier

—

Countries

India

Contacts

Public ContactDr V J Ramesh

NIMHANS

drvjramesh@gmail.com9844432607

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026